Evidence map›Paper›PMID 41089705›Full record

ArticleFrontiers in immunology2025

Identification of novel genetic biomarkers for ChAdOx1 nCoV-19 mediated immunogenicity.

Wan-Hsuan Chou, Che-Mai Chang, Jafit Ting, Min-Rou Lin, Hsin-Ni Liao, Yi-Chien Chou, Chun-Yu Wei, Hsin-Hui Chi, Szu-Ying Ho, Wei-Tzu Luo and 12 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Wan-Hsuan ChouDepartment of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Che-Mai ChangDepartment of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Jafit TingDepartment of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Min-Rou LinDepartment of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Hsin-Ni LiaoDepartment of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Yi-Chien ChouDepartment of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Chun-Yu WeiDepartment of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Hsin-Hui ChiDepartment of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Szu-Ying HoDepartment of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Wei-Tzu LuoDepartment of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Cheng-Lin TsaiDepartment of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Ching-Hsuan ChaoDepartment of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Lu-Chun ChenDepartment of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Tsung-Hsun WuDepartment of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Wei-Chih LiuDepartment of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Quynh-Anh NguyenDepartment of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Hui-Wen ChangSchool of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Ching-Sheng HungDepartment of Laboratory Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Shiao-Ya HongDepartment of Biotechnology and Laboratory Science in Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Jude Chu-Chun WangDivision of Pulmonary Medicine, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
Shih-Hsin HsiaoDivision of Pulmonary Medicine, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
Wei-Chiao ChangDepartment of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Research comprehensively examining factors for COVID-19 DNA vaccine responses is lacking, particularly in Asian populations. This study aims to investigate biomarkers of reactogenic and immunogenic responses after DNA-based COVID-19 vaccination in a Taiwanese population. Methods: A genome-wide association study (GWAS) of 415 Taiwanese healthcare workers was conducted to identify genetic variants associated with reactogenic and immunogenic responses to the first and second doses of ChAdOx1 nCoV-19 vaccine. Furthermore, gene set enrichment analysis was conducted to elucidate the underlying biological pathways. Finally, a polygenic score (PGS) was utilized to assess the synergistic host effects on neutralizing antibody (NT50). Results: We identified 501 suggestive significant genetic associations with vaccine responses, enriched in lipid and lipophilic vitamin metabolism, interleukin signaling, and neurotransmitter release pathways. Moreover, we observed a combined effect of genetics with age and sex on NT50 after the second dose. Notably, the negative correlation between age and NT50 was stronger in lower PGS groups (ρ Conclusion: Our study fills a critical gap by addressing the lack of research on genetic factors of ChAdOx1 nCoV-19 vaccine responses in Asian population, providing valuable insights into the genetic basis of DNA-based vaccine responses. The synergic host effect highlights the value of integrating genetic information with other host factors as a biomarker to predict individual vaccine responses. Our findings can contribute to personalized vaccination strategies and future vaccination policies.

Indexed as

ChAdOx1 nCoV-19COVID-19COVID-19 VaccinesImmunogenicity, VaccineSARS-CoV-2AdultAntibodies, NeutralizingAntibodies, ViralFemaleGenetic MarkersGenome-Wide Association StudyHumansMaleMiddle AgedPolymorphism, Single NucleotideTaiwanAntibodies, NeutralizingAntibodies, ViralChAdOx1 nCoV-19COVID-19 VaccinesGenetic MarkersVaccines, DNAbiomarkerCOVID-19 vaccine responsesgenomicshost factorspolygenic effect

Identifiers

PMID41089705
PMCPMC12515888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.